Related Experiment Video
Updated: May 7, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer
1Medical Oncology Department; University Hospital La Paz; IdiPAZ; Madrid, Spain.
Abstract:
Prostate cancer is a heterogeneous disease where the previous concept of "hormone resistance" has been changed by a new generation of hormonal therapies that have proven efficacy in the castration-resistant setting. The fact is that androgens play a crucial role in the whole clinical course of prostate cancer, even when a patient meets castration-resistance criteria. The development of abiraterone showed how important and clinically meaningful can be to achieve the lowest possible levels of testosterone, and androgen receptor overexpression, mutation, or enhanced crosstalk with other pathways, which can also be targeted with new agents tested in the last few years. New androgen biosynthesis inhibitors have been developed, such as orteronel (TAK-700), but also new antiandrogens (enzalutamide, ARN-509, ODM-201) or even agents with a dual mechanism of action (galeterone). In this review the development of new hormonal therapies following the arrival of abiraterone for the treatment of prostate cancer will be summarized.
Insights
New hormonal therapies are revolutionizing prostate cancer treatment, moving beyond traditional hormone resistance. These advanced treatments target androgens and androgen receptors, offering new hope for patients with castration-resistant prostate cancer.
Area of Science:
- Oncology
- Urology
- Endocrinology
Background:
- Prostate cancer's progression involves androgens even in castration-resistant stages.
- The concept of hormone resistance is evolving with new therapeutic strategies.
- Androgen receptor (AR) signaling remains critical throughout prostate cancer's clinical course.
Purpose of the Study:
- To review the development of novel hormonal therapies for prostate cancer post-abiraterone.
- To summarize agents targeting androgen biosynthesis and androgen receptor pathways.
- To highlight advancements in managing castration-resistant prostate cancer.
Main Methods:
- Literature review of recent clinical studies and drug development.
- Analysis of novel agents targeting androgen pathways.
- Summary of therapeutic strategies for advanced prostate cancer.
Main Results:
- Abiraterone established the clinical benefit of profound testosterone suppression.
- New androgen biosynthesis inhibitors (e.g., orteronel) and novel antiandrogens (e.g., enzalutamide, ARN-509, ODM-201) show efficacy.
- Agents with dual mechanisms (e.g., galeterone) are under investigation.
Conclusions:
- Hormonal therapies continue to evolve, offering improved outcomes for prostate cancer patients.
- Targeting androgen pathways remains a cornerstone in managing advanced prostate cancer.
- The development of new agents provides more options for castration-resistant disease.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...